Dr. Oreste Gualillo

SERGAS, Santiago University Clinical Hospital, Spain





1996  Ph.D., Department of Experimental Pharmacology, University of Naples “Federico II”, Italy

1991  Pharm.D., Department of Department of Experimental Pharmacology, University of Naples “Federico II”, Italy


Publications (Selected)

  1. Conde J, Scotece M, Lopez V, Gomez R, Lago F, Pino J, Gomez-Reino JJ, GualilloO. Expression and modulation of adipolin/C1qdc2: a novel adipokine in human andmurine ATDC-5 chondrocytecell line. Ann RheumDis. 2012 Jun 26. [Epubaheadofprint] PubMed PMID: 22736092.
  2. Scotece M, Conde J, Gomez R, Lopez V, Pino J, Gonzalez A, Lago F, Gomez-Reino JJ, Gualillo O.Role of Adipokines in Atherosclerosis: Interferenceswith Cardiovascular Complications in RheumaticDiseases. Mediators of Inflammation, 2012 doi:10.1155/2012/125458
  3. Conde J, Scotece M, Gomez R, Lopez V, Gomez-Reino JJ, Lago F and OresteGualillo. Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism and immunity.Biofactors, 2011 Nov-Dec;37(6):413-20.doi: 10.1002/biof.185.
  4. Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F and Gualillo O. What’s new in our understanding of the role of adipokines in rheumatic diseases? Nature Reviews Rheumatology, 2011 Aug 2;7(9):528-36. doi: 10.1038/nrrheum.2011.107.
  5. Rodriguez Penas D, Feijoo-Bandin S, Lear PV, Mosquera-Leal A, García –Rua V, Otero MF, Rivera M, Gualillo O, Gonzalez-Juanatey JR, Lago F. Aliskiren affects fatty-acid uptake and lipid-related genes in rodent and human cardiomyocytes. BiochemPharmacol,2011 Sep 1;82(5):491-504. 2011; doi: 10.1016/j.bcp.2011.05.021
  6. Gomez R, Scotece M, Conde J, Gomez-Reino JJ, Lago F, Gualillo O. Adiponectin and leptin increase IL-8 production in human chondrocytes. Ann Rheum Dis. 2011 Nov;70(11):2052-4.doi 10.1136/ard.2010.145672.
  7. Lago F, Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Gualillo O. Cardiometabolic comorbidities and rheumatic diseases: Focus on the role of fat mass and adipokines. Arthritis Care Res (Hoboken), 2011,63(8):1083-90.doi:10.1002/acr.20488. PubMed PMID: 21523926.
  8. Conde J, Gomez R, Bianco G, Scotece M, Lear P, Dieguez C, Gomez-Reino J, LagoF, Gualillo O. Expanding the adipokine network in cartilage: identification andregulation of novel factors in human and murine chondrocytes. Ann Rheum Dis. 2011; 70(3):551-559. PubMed PMID: 21216818.
  9. Iacono A, Gómez R, Sperry J, Conde J, Bianco G, Meli R, Gómez-Reino JJ, Smith AB 3rd, Gualillo O. Effect of oleocanthal and its derivatives on inflammatory response induced by lipopolysaccharide in a murine chondrocyte cell line. Arthritis Rheum. 2010 Jun; 62(6):1675-82.PMID: 20201078
  10. Lago F, Gómez R, Gómez-Reino JJ, Dieguez C, Gualillo O. Adipokines as novel modulators of lipid metabolism. Trends Biochem Sci. 2009 Oct; 34(10):500-10. PubMed PMID: 19729309.
  11. Gómez R, Lago F, Gómez-Reino JJ, Dieguez C, Gualillo O. Expression andmodulation of ghrelin O-acyltransferase in cultured chondrocytes. ArthritisRheum. 2009 Jun;60(6):1704-9. PubMed PMID: 19479831.
  12. Gómez R, Lago F, Gómez-Reino JJ, Gualillo O. Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin. Expert OpinTher Targets.2009 May;13(5):583-91. PubMed PMID: 19397477.
  13. Gualillo O, Lago F, Dieguez C. Introducing GOAT: a target for obesity and anti-diabetic drugs? Trends Pharmacol Sci. 2008 Aug;29(8):398-401
  14. Lago R, Gomez R, Otero M, Lago F, Gallego R, Dieguez C, Gomez-Reino JJ, Gualillo O. A new player in cartilage homeostasis: adiponectin induces nitricoxide synthase type II and pro-inflammatory cytokines in chondrocytes.Osteoarthritis Cartilage. 2008 Sep;16(9):1101-9. Epub 2008 Feb 7. PubMed PMID:18261936.
  15. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. Adipokines as emerging mediatorsof immune response and inflammation. Nat ClinPractRheumatol. 2007Dec;3(12):716-24. PubMed PMID: 18037931.
  16. Gualillo O, González-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives.TrendsCardiovasc Med. 2007 Nov;17(8):275-83. PubMed PMID: 18021938.
  17. Lago R, Gomez R, Dieguez C, Gomez-Reino JJ, Lago F, Gualillo O. Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes. Ann Rheum Dis. 2007 Oct;66(10):1399-400. PubMed PMID: 17881664. IF:7.792 Q1
  18. Gualillo O. Further evidence for leptin involvement in cartilage homeostasis Osteoarthritis Cartilage. 2007 Aug;15(8):857-60. Epub 2007 Jun 8. PubMed PMID:17560812.
  19. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev.2007 Jun-Aug;18(3-4):313-25. Epub 2007 May 15. PubMed PMID: 17507280.
  20. Otero M, Lago R, Gomez R, Dieguez C, Lago F, Gómez-Reino J, Gualillo O. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford). 2006 Aug;45(8):944-50. Epub 2006 May 23. PubMedPMID: 16720637.
  21. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gómez-Reino JJ, Gualillo O. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistinandvisfatin in patients with rheumatoid arthritis. Ann Rheum Dis. 2006Sep;65(9):1198-201. Epub 2006 Jan 13. PubMed PMID: 16414972; PubMed CentralPMCID: PMC1798289.
  22. Otero M, Lago R, Lago F, Reino JJ, Gualillo O. Signalling pathway involved innitric oxide synthase type II activation in chondrocytes: synergistic effect ofleptin with interleukin-1. Arthritis Res Ther.2005;7(3):R581-91. Epub 2005 Mar4. PubMed PMID: 15899045; PubMed Central PMCID: PMC1174950.
  23. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gómez-Reino JJ, GualilloO.Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 2005Jan 17;579(2):295-301. PubMed PMID: 15642335.
  24. Otero M, Gomez Reino JJ, Gualillo O. Synergistic induction of nitric oxide synthase type II: in vitro effect of leptin and interferon-gamma in human chondrocytes and ATDC5 chondrogenic cells. Arthritis Rheum. 2003 Feb;48(2):404-9.PubMed PMID: 12571850.